Compugen (CGEN) Receivables (2009 - 2024)

Compugen's (CGEN) quarterly Receivables came in at $5.0 million in Q2 2024, down 91.8% quarter-over-quarter from $61.0 million in Q4 2023.

Compugen (CGEN) Receivables (2009 - 2024) Analysis & Trends

Compugen has disclosed Receivables across 10 years of filings, most recently posting $5.0 million for Q2 2024.

Receivables for Q2 2024 came in at $5.0 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2024 was $5.0 million (changed N/A YoY), and the FY2023 annual result was $61.0 million, changed N/A from the prior year.
Receivables came in at $5.0 million for Q2 2024 at Compugen, down from $61.0 million in the prior quarter.
In the past five years, Receivables ranged from a high of $61.0 million in Q4 2023 to a low of $2.0 million in Q4 2020.
The 4-year median for Receivables is $5.5 million (2021), against an average of $18.5 million.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	13.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	2.00 Bn
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Compugen	189.59 Mn	97.83 Mn	352,000.00	-

Download Data